TrialArthritis & rheumatology (Hoboken, N.J.)2017

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.

Michael E Weinblatt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.